Cellectar Biosciences Files 8-K

TL;DR

Cellectar filed an 8-K on Nov 15, 2024, updating corporate and financial info.

AI Summary

Cellectar Biosciences, Inc. filed an 8-K on November 15, 2024, reporting other events and financial statements. The company, incorporated in Delaware, has its principal executive offices in Florham Park, NJ. It was formerly known as Novelos Therapeutics, Inc. and Common Horizons Inc.

Why It Matters

This filing provides an update on Cellectar Biosciences' corporate and financial status, which is important for investors to track the company's ongoing activities and disclosures.

Risk Assessment

Risk Level: low — This is a routine filing of an 8-K, which typically reports significant events or financial updates without inherently introducing new risks.

Key Players & Entities

• Cellectar Biosciences, Inc. (company) — Registrant
• November 15, 2024 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• Florham Park, NJ (location) — Address of principal executive offices
• Novelos Therapeutics, Inc. (company) — Former company name
• Common Horizons Inc (company) — Former company name

FAQ

Key Financial Figures

• $0.00001 — ch registered Common Stock, par value $0.00001 per share CLRB The Nasdaq Capital M

Filing Documents

• tm2428581d1_8k.htm (8-K) — 26KB
• tm2428581d1_ex23-1.htm (EX-23.1) — 2KB
• 0001104659-24-119738.txt ( ) — 197KB
• clrb-20241115.xsd (EX-101.SCH) — 3KB
• clrb-20241115_lab.xml (EX-101.LAB) — 33KB
• clrb-20241115_pre.xml (EX-101.PRE) — 22KB
• tm2428581d1_8k_htm.xml (XML) — 3KB

01

Item 8.01. Other Events . On October 29, 2024, Cellectar Biosciences, Inc. (the "Company") filed an amended Annual Report on Form 10-K/A for the fiscal year ended December 31, 2023 (the "Form 10-K/A") with the Securities and Exchange Commission (the "SEC"). Due to an inadvertent omission, the consent of the Company's independent registered public accounting firm dated October 29, 2024 and filed as Exhibit 23.1 to the Form 10-K/A did not include a reference to the Company's following registration statements on Form S-1 (File Nos. 333-208638, 333-214310, 333-225675, 333-231888, 333-238132, and 333-268554), Form S-1 MEF (File Nos. 333-226374 and 333-238892), and Form S-3 (File Nos. 333-208189, 333-252309, 333-274880 and 333-279731). The correct consent of the Company's independent registered public accounting firm dated November 15, 2024 (the "Revised Consent") is attached as Exhibit 23.1 to this Current Report on Form 8-K and is hereby filed with the SEC. The Revised Consent does not change any previously reported financial results or other disclosure contained in the Form 10-K.

Financial Statements and Exhibits

Financial Statements and Exhibits (d) Exhibits Number Title 23.1 Consent of Independent Registered Public Accounting Firm 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CELLECTAR BIOSCIENCES, INC. Date: November 15, 2024 By: /s/ Chad J. Kolean Name: Chad J. Kolean Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR